Tactile Systems Technology Inc (TCMD) shareholders
Close on Nov 17, 2026Market cap $590.09MP/E 25.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 1,818,693 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Eric Bannasch Joint filing with Cadian Capital Management, LP (7.00%), Cadian Capital Management GP, LLC (7.00%) | 1,576,940 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,905,086 | 8.41% | $56.73M | +125,640 | 0.00% |
| Cadian Capital Management, LP | 1,576,940 | 6.96% | $46.96M | +535,868 | 3.55% |
| Dimensional Fund Advisors LP | 1,092,193 | 4.82% | $32.53M | +12,477 | 0.01% |
| Morgan Stanley | 979,340 | 4.32% | $29.16M | −403,472 | 0.00% |
| Vanguard Capital Management LLC | 970,246 | 4.28% | $28.89M | +25,149 | 0.00% |
| Driehaus Capital Management LLC | 937,783 | 4.14% | $27.93M | +195,869 | 0.16% |
| Acadian Asset Management LLC | 903,553 | 3.99% | $26.90M | −1,816 | 0.03% |
| Vanguard Portfolio Management LLC | 706,509 | 3.12% | $21.04M | +38,175 | 0.00% |
| Federated Hermes, Inc. | 681,153 | 3.01% | $20.28M | +20,196 | 0.03% |
| Arrowstreet Capital, Limited Partnership | 638,368 | 2.82% | $19.01M | – | 0.01% |
| Geode Capital Management, LLC | 586,334 | 2.59% | $17.47M | +29,540 | 0.00% |
| State Street Corp | 576,134 | 2.54% | $17.16M | +7,708 | 0.00% |
| Next Century Growth Investors LLC | 480,207 | 2.12% | $14.30M | +52,048 | 0.76% |
| Lsv Asset Management | 479,927 | 2.12% | $14.29M | – | 0.03% |
| Renaissance Technologies LLC | 474,100 | 2.09% | $14.12M | −36,797 | 0.02% |
| First Light Asset Management, LLC | 462,562 | 2.04% | $13.78M | New | 0.84% |
| Jupiter Topco LLC | 397,278 | 1.75% | $11.83M | New | 0.00% |
| Pinnacle Associates Ltd | 327,117 | 1.44% | $9.74M | +311 | 0.11% |
| Punch & Associates Investment Management, Inc. | 315,000 | 1.39% | $9.38M | +15,000 | 0.46% |
| Dana Investment Advisors, Inc. | 306,209 | 1.35% | $9.12M | New | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 22M | 96.7% | 29 / 82 | 44 / 30 | 3M | 3M |
| Q1 2026 | 185 | 21M | 94.8% | 41 / 65 | 58 / 21 | 5M | 2M |
| Q4 2025 | 169 | 21M | 91.0% | 51 / 53 | 48 / 8 | 5M | 5M |
| Q3 2025 | 126 | 20M | 89.8% | 17 / 49 | 38 / 17 | 1M | 2M |
| Q2 2025 | 127 | 21M | 92.9% | 14 / 41 | 56 / 27 | 3M | 3M |
| Q1 2025 | 140 | 22M | 96.0% | 22 / 43 | 53 / 21 | 3M | 2M |
| Q4 2024 | 141 | 21M | 93.4% | 37 / 39 | 42 / 25 | 2M | 3M |
| Q3 2024 | 130 | 22M | 97.5% | 26 / 45 | 35 / 27 | 5M | 3M |
| Q2 2024 | 132 | 23M | 99.5% | 22 / 53 | 40 / 28 | 4M | 4M |
| Q1 2024 | 138 | 23M | 100.0% | 29 / 39 | 49 / 23 | 5M | 2M |
| Q4 2023 | 132 | 20M | 88.4% | 22 / 46 | 42 / 45 | 5M | 5M |
| Q3 2023 | 155 | 20M | 89.8% | 33 / 59 | 44 / 28 | 5M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
226 funds held TCMD in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TCMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 686,535 | 3.03% | $20.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 598,451 | 2.64% | $17.82M | 0.02% | Jun 30, 2026 |
| Janus Henderson Small Cap Value Fund | 397,237 | 1.75% | $11.83M | 0.93% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 329,945 | 1.46% | $9.29M | 0.41% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 261,835 | 1.16% | $7.80M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 250,114 | 1.10% | $7.05M | 0.02% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 240,781 | 1.06% | $5.93M | 0.02% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 190,594 | 0.84% | $5.68M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 179,648 | 0.79% | $5.35M | 0.03% | Jun 30, 2026 |
| U.S. Targeted Value Portfolio | 163,645 | 0.72% | $4.61M | 0.03% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 157,800 | 0.70% | $4.45M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Targeted Value ETF | 147,758 | 0.65% | $4.16M | 0.03% | Jul 31, 2026 |
| Driehaus Micro Cap Growth Fund | 147,581 | 0.65% | $4.39M | 0.74% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 130,500 | 0.58% | $3.89M | 0.03% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 121,214 | 0.54% | $3.61M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sheri Louise Dodd | Chief Executive Officer, Director | 232,907 | 1.03% | Aug 12, 2026 |
| Stephen A. Kiewiet | Chief Operating Officer | 6,438 | 0.03% | Nov 6, 2026 |
| Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | 130,188 | 0.57% | May 13, 2026 |
| Kristie Burns | Sr. VP Mktg & Clinical Affairs | 82,581 | 0.36% | Feb 26, 2026 |
| William W. Burke | Director | 50,041 | 0.22% | Nov 9, 2026 |
| Laura G. King | Director | 20,769 | 0.09% | Nov 5, 2026 |
| Boyd Vindell Washington | Director | 41,768 | 0.18% | May 8, 2026 |
| Andrea Pearson | Director | 7,373 | 0.03% | May 8, 2026 |
| Carmen B. Volkart | Director | 44,219 | 0.20% | May 8, 2026 |
| Raymond Huggenberger | Director | 62,841 | 0.28% | May 8, 2026 |
| Valerie L. Asbury | Director | 55,343 | 0.24% | May 8, 2026 |
| David Brent Shafer | Director | 55,343 | 0.24% | May 8, 2026 |
| Daniel L. Reuvers | Director | 214,604 | 0.95% | Mar 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| William W. Burke Director | Nov 4, 2026 | Sale(10b5-1 plan) | −5,000 | $27.00 | $135.00K | 50,041 |
| Stephen A. Kiewiet Chief Operating Officer | Nov 4, 2026 | Award | +6,438 | – | – | 6,438 |
| Laura G. King Director | Nov 3, 2026 | Sale(10b5-1 plan) | −4,800 | $25.00 | $120.00K | 20,769 |
| Sheri Louise Dodd Chief Executive Officer, Director | Aug 10, 2026 | Sale | −10,978 | $29.44 | $323.19K | 232,907 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | May 11, 2026 | Sale | −4,631 | $24.49 | $113.41K | 130,188 |
| Boyd Vindell Washington Director | May 6, 2026 | Award | +6,521 | – | – | 41,768 |
| Valerie L. Asbury Director | May 6, 2026 | Award | +6,521 | – | – | 55,343 |
| Raymond Huggenberger Director | May 6, 2026 | Award | +6,521 | – | – | 62,841 |
| Laura G. King Director | May 6, 2026 | Award | +6,521 | – | – | 25,569 |
| Carmen B. Volkart Director | May 6, 2026 | Award | +6,521 | – | – | 44,219 |
| William W. Burke Director | May 6, 2026 | Award | +6,521 | – | – | 55,041 |
| David Brent Shafer Director | May 6, 2026 | Award | +6,521 | – | – | 55,343 |
| Andrea Pearson Director | May 6, 2026 | Award | +6,521 | – | – | 7,373 |
| Andrea Pearson Director | Mar 9, 2026 | Award | +852 | – | – | 852 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 24, 2026 | Sale | −10,993 | $28.94 | $318.14K | 243,885 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 24, 2026 | Sale | −7,701 | $28.94 | $222.87K | 134,819 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 24, 2026 | Sale | −6,246 | $28.94 | $180.76K | 82,581 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 23, 2026 | Sale | −160 | $28.69 | $4.59K | 88,827 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 23, 2026 | Sale | −4,279 | $28.28 | $121.01K | 88,987 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −196 | $28.69 | $5.62K | 142,520 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −5,322 | $28.28 | $150.51K | 142,716 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 23, 2026 | Sale | −537 | $28.69 | $15.41K | 254,878 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 23, 2026 | Sale | −14,703 | $28.28 | $415.80K | 255,415 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +3,490 | – | – | 82,085 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +4,058 | – | – | 86,143 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +7,123 | – | – | 93,266 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +15,575 | – | – | 148,038 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +6,765 | – | – | 132,463 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +3,579 | – | – | 125,698 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2026 | Award | +19,751 | – | – | 241,902 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2026 | Award | +28,216 | – | – | 270,118 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 19, 2026 | Award | +6,194 | – | – | 78,595 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 19, 2026 | Award | +23,008 | – | – | 122,119 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 19, 2026 | Award | +48,672 | – | – | 222,151 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Jan 2, 2026 | Sale(10b5-1 plan) | −5,139 | $28.85 | $148.26K | 72,401 |
| Sheri Louise Dodd Chief Executive Officer, Director | Aug 8, 2025 | Sale | −7,762 | $12.36 | $95.94K | 173,479 |
| Elaine M. Birkemeyer Chief Financial Officer | May 12, 2025 | Sale(10b5-1 plan) | −2,921 | $9.94 | $29.03K | 99,111 |
| Sheri Louise Dodd Chief Executive Officer, Director | May 8, 2025 | Sale | −3,149 | $9.83 | $30.95K | 181,241 |
| William W. Burke Director | May 8, 2025 | Sale(10b5-1 plan) | −3,300 | $9.67 | $31.91K | 48,520 |
| Boyd Vindell Washington Director | May 7, 2025 | Award | +16,078 | – | – | 35,247 |
| David Brent Shafer Director | May 7, 2025 | Award | +16,078 | – | – | 48,822 |
| Valerie L. Asbury Director | May 7, 2025 | Award | +16,078 | – | – | 48,822 |
| Laura G. King Director | May 7, 2025 | Award | +16,078 | – | – | 19,048 |
| Raymond Huggenberger Director | May 7, 2025 | Award | +16,078 | – | – | 56,320 |
| Carmen B. Volkart Director | May 7, 2025 | Award | +16,078 | – | – | 37,698 |
| William W. Burke Director | May 7, 2025 | Award | +16,078 | – | – | 51,820 |
| Daniel L. Reuvers Director | Mar 11, 2025 | Gift | −68,162 | – | – | 146,442 |
| Daniel L. Reuvers Director | Mar 11, 2025 | Gift | +68,162 | – | – | 68,162 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 25, 2025 | Sale | −6,468 | $14.40 | $93.14K | 77,540 |
| Daniel L. Reuvers Director | Feb 25, 2025 | Sale(10b5-1 plan) | −28,338 | $14.18 | $401.83K | 214,604 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 25, 2025 | Sale(10b5-1 plan) | −2,066 | $14.51 | $29.98K | 102,032 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 24, 2025 | Sale(10b5-1 plan) | −3,778 | $14.70 | $55.54K | 104,098 |
| Daniel L. Reuvers Director | Feb 24, 2025 | Sale(10b5-1 plan) | −10,938 | $14.55 | $159.15K | 242,942 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 24, 2025 | Sale | −4,830 | $14.65 | $70.76K | 84,008 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +6,887 | – | – | 71,628 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +3,446 | – | – | 64,741 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +36,248 | – | – | 107,876 |
| Laura G. King Director | Feb 20, 2025 | Award | +2,970 | – | – | 2,970 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2025 | Award | +65,669 | – | – | 184,390 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2025 | Award | +20,108 | – | – | 118,721 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tactile Systems Technology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,140 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Laura G. King Director | Nov 3, 2026 | 4,800 | $120.00K | Nov 3, 2026 | Restricted Stock Vesting |
| William W. Burke board of director | Aug 20, 2026 | 15,000 | $540.26M | Aug 19, 2026 | Restricted |
| Sheri Louise Dodd Officer, Director | Aug 10, 2026 | 10,978 | $323.24K | Aug 10, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | May 11, 2026 | 4,631 | $113.40K | May 11, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 25, 2026 | 4,000 | $113.88K | Feb 25, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Feb 24, 2026 | 10,993 | $318.15K | Feb 24, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | Feb 24, 2026 | 7,701 | $222.87K | Feb 24, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 24, 2026 | 6,246 | $180.77K | Feb 24, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | Feb 23, 2026 | 5,518 | $156.14K | Feb 23, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 23, 2026 | 4,439 | $125.61K | Feb 23, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Feb 23, 2026 | 15,240 | $431.25K | Feb 23, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Jan 2, 2026 | 5,139 | $148.26K | Jan 2, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Aug 8, 2025 | 7,762 | $95.91K | Aug 8, 2025 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | May 12, 2025 | 2,921 | $29.04K | May 12, 2025 | Vesting of restricted stock unit award |
| Sheri Louise Dodd Director | May 8, 2025 | 3,149 | $30.95K | May 8, 2025 | Vesting of restricted stock unit award |
See a number that looks wrong?